LON:CLL - Cello Health plc (CLL.L) Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: GBX 0
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 161
+0 (0.00%)

This chart shows the closing price for CLL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cello Health plc (CLL.L) Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CLL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CLL

Analyst Price Target is GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Cello Health plc (CLL.L) in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 161.

This chart shows the closing price for CLL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Cello Health plc (CLL.L). This rating has held steady since May 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/15/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/16/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/14/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/12/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/10/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/11/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/10/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/9/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/20/2020Liberum CapitalReiterated RatingHoldGBX 120
5/20/2020FinnCapReiterated RatingCorporate
4/8/2020Liberum CapitalLower Price TargetHoldGBX 125 ➝ GBX 120
4/7/2020FinnCapReiterated RatingCorporate
3/19/2020FinnCapReiterated RatingCorporate
3/18/2020Liberum CapitalReiterated RatingHold
2/6/2020Liberum CapitalReiterated RatingHold
1/17/2020FinnCapReiterated RatingCorporate
1/16/2020Liberum CapitalReiterated RatingHold
9/30/2019Liberum CapitalInitiated CoverageHoldGBX 135
9/24/2019FinnCapReiterated RatingCorporate
8/21/2019FinnCapBoost Price TargetCorporateGBX 145 ➝ GBX 160
7/18/2019FinnCapReiterated RatingCorporate
5/8/2019FinnCapReiterated RatingCorporate
3/27/2019FinnCapReiterated RatingCorporate
3/21/2019FinnCapReiterated RatingCorporate
1/17/2019FinnCapReiterated RatingCorporate
9/19/2018FinnCapReiterated RatingCorporate
7/23/2018FinnCapReiterated RatingCorporate
5/9/2018FinnCapReiterated RatingCorporate
12/4/2017FinnCapReiterated RatingBuyGBX 135
9/26/2017FinnCapReiterated RatingBuyGBX 132
9/20/2017N+1 SingerReiterated RatingBuyGBX 131
9/20/2017FinnCapReiterated RatingBuyGBX 132
(Data available from 8/9/2017 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/11/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/10/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/12/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/11/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/11/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/10/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/10/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/9/2022

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Cello Health plc (CLL.L) logo
Cello Health plc, together with its subsidiaries, provides marketing services in the United Kingdom, Rest of Europe, the United States, and internationally. It operates in two segments, Cello Health and Cello Signal. The Cello Health segment offers market research, consulting, and communications services principally to the pharmaceutical and healthcare clients. The Cello Signal segment provides market research and direct communications services principally to consumer-facing clients. Cello Health plc was incorporated in 2004 and is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: GBX 161
Low: 161
High: 161

50 Day Range

MA: GBX 161
Low: 161
High: 161

52 Week Range

Now: GBX 161
Low: 100
High: 165

Volume

N/A

Average Volume

453,244 shs

Market Capitalization

£178.84 million

P/E Ratio

N/A

Dividend Yield

1.34%

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Cello Health plc (CLL.L)?

The following Wall Street research analysts have issued stock ratings on Cello Health plc (CLL.L) in the last twelve months:
View the latest analyst ratings for CLL.

What is the current price target for Cello Health plc (CLL.L)?

0 Wall Street analysts have set twelve-month price targets for Cello Health plc (CLL.L) in the last year. has the lowest price target set, forecasting a price of £100,000 for Cello Health plc (CLL.L) in the next year.
View the latest price targets for CLL.

What is the current consensus analyst rating for Cello Health plc (CLL.L)?

Cello Health plc (CLL.L) currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for CLL.

What other companies compete with Cello Health plc (CLL.L)?

Other companies that are similar to Cello Health plc (CLL.L) include Ebiquity, Science Group, De La Rue, M&C Saatchi and The Pebble Group. Learn More about companies similar to Cello Health plc (CLL.L).

How do I contact Cello Health plc (CLL.L)'s investor relations team?

Cello Health plc (CLL.L)'s physical mailing address is 11-13 Charterhouse Buildings, LONDON, EC1M 7AP, United Kingdom. The company's listed phone number is +44-20-78128460. The official website for Cello Health plc (CLL.L) is www.cellogroup.com. Learn More about contacing Cello Health plc (CLL.L) investor relations.